Interní Med. 2018; 20(2): 85-88 | DOI: 10.36290/int.2018.052

Direct anticoagulants and their new indications

MUDr. Kateřina Gončarová^1,2, doc. MUDr. Ondřej Ludka, Ph.D.^1,2,3

¹ Interní kardiologická klinika FN Brno

² Lékařská fakulta MU Brno

³ Mezinárodní centrum klinického výzkumu, FN u sv. Anny v Brně

Direct anticoagulants have become increasingly popular in recent years. Their benefits include, among other things, ease ofapplication, high safety and the absence of the need for regular monitoring. The well-known and validated indications are theprevention of thromboembolic events in patients with non-valvular atrial fibrillation, post-orthopedic surgery, treatment andprevention of venous thrombosis and pulmonary embolism. In actual article we mention relatively new knowledges about theuse of direct anticoagulations in patients before cardioversion, catheter ablation or after percutaneous coronary intervention.

Keywords: new oral anticoagulants, dabigatran, apixaban, rivaroxaban, edoxaban, atrial fibrilation, catheter ablation, percutaneous
coronary intervention

Received: February 9, 2017; Accepted: April 4, 2017; Published: May 1, 2018  Show citation